Use of social media concepts to put scientists in control of how they do Open innovation compound sharing

1. Compound Passport
Dr David Andrews
Bio2Business Outsourcing Strategies (BOS) 22nd September 2015

2. AstraZeneca’s Open Innovation Portal
Towards Delivering Breakthrough Medicines
2
Clinical
compound
bank
Pharamacology
toolbox
Target
innovation
New
Molecule
profiling
R&D
Challenges
Suggestion
box
openinnovation.astrazeneca.com

3. Topushtheboundariesofsciencetodeliverlife-changing
medicines
>20 Clinical ready
compounds
>40 Mechanistic
tool compounds
Up to 250K screening
compounds or full HTS
Screening &DMPK data
Potential to partner
Prizes for solutions
to R&D challenges
Partnerships
New clinically validated
projects
New lead optimization projects
New targets/hit ID projects
Access to novel molecules
Novel solutions
Clinical Compound
Bank
Pharmacology
Toolbox
Target Innovation
New Molecule
Profiling
R&D Challenges
Suggestion Box
Ideas for future
partnerships
Academics
The Opportunity
AZ
GenerationofNoveldataforpublicationsandadvance
medicalscience

4. The Problem:
Managing compound asset rights
4
We need to ensure that any compound
subject to a contractual agreement
with a 3rd party is managed and used
in accordance with AZ’s obligations
under such a contract
Examples:
Compounds with shared IP are restricted to agreed tests
Compounds under a shared agreement cannot be shared
with others…

5. Which Country to I
belong to?
Originating
Organisation
Where can I travel?
Where can this asset
be tested?
Where have I been?
Which collaboration
partners have had
access to this asset?
A Passport Service for Compounds
5

6. The Solution
....a Compound Passport Service
Record Shared Assets
•Set up Asset Rights Group
•Add compounds
Update Asset Status
•Modify compound ownership
•Modify ‘allowed for test’ status
Approve test requests
•Automatic approval
•Manual Approval
Check Asset History
•Is the compound locked with a
collaborator?
•View asset history

7. Compound Passport Service Impact
7
• Since its launch in November 2014, CPS now tracks and protects ~32,000
compound assets
• CPS has already proven its value: -
– A simple check in CPS identified that two separate Open Innovation
collaborations had requested the same chemical series
– ~4000 compounds searched in minutes to confirm divest rights, something
that previously would have taken days
– Easy to check that compound usage is compliant with agreements by
viewing the Asset Rights Group approval history

8. The future of Compound Passport Service
8
CPS
Flag ARG
status in
compound
search
Test
request
approval
Manage
external
sharing
ARG
assignment
at
registration
Future
system
integrations
Control
compound
distribution
• Delivering Compound Passport as a component
service on the AZ SOA platform has made it a
flexible, re-usable utility for an array of
consumers.
• The Asset Rights Groups (ARG) concept
underpinning CPS could be extended for non-
small molecule assets.
• With the emergence of cross-industry, National
and International Compound Collections, it is
conceivable that flexible solutions like CPS will
be able to work with national compound
databases and allow collaboration partners to
view the status of their compounds in real time.

9. Summary
9
• We have developed a flexible service to effectively manage the rights
associated with our compound assets
• The Compound Passport Service has improved asset rights compliance and
process efficiency in test request management
• CPS is enabling AstraZeneca’s R&D strategy for Open Innovation and
collaborative science.
• Find out more at:
http://www.sciencedirect.com/science/article/pii/S135964461500241X#
doi:10.1016/j.drudis.2015.06.011

10. Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the
contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000,
F: +44 (0)20 7604 8151, www.astrazeneca.com
10